The Bio Report
Addressing the Challenge of Producing Stem Cell Therapies with Consistency at Scale
- Autor: Vários
- Narrador: Vários
- Editora: Podcast
- Duração: 0:29:23
- Mais informações
Informações:
Sinopse
Mesenchymal stem cells may be a powerful way to treat a range of medical conditions but realizing the therapeutic potential of these cells has been hampered in part by the challenges of manufacturing a consistent product at scale. Cynata Therapeutics believes its platform technology addresses these challenges. The company lead cell therapy candidate is being developed to treat graft vs. host disease, a potentially deadly response to the transplantation of cells from a donor. We spoke to Ross MacDonald, CEO of Cynata, about the company’s platform technology, the potential for these therapies, and the indications the company is pursuing.